Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in thetreatment of advanced malignant pleural mesothelioma - A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)
Autore:
Parra, HS; Tixi, L; Latteri, F; Bretti, S; Alloisio, M; Gravina, A; Lionetto, R; Bruzzi, P; Dani, C; Rosso, R; Cosso, M; Balzarini, L; Santoro, A; Ardizzoni, A;
Indirizzi:
Ist Clin Humanitas, Dept Med Oncol & Hematol, I-20089 Rozzano Milano, Italy Ist Clin Humanitas Rozzano Milano Italy I-20089 89 Rozzano Milano, Italy Grp Italiano Tumori Rari, Rozzano Milano, Italy Grp Italiano Tumori Rari Rozzano Milano Italy ri, Rozzano Milano, Italy Ist Nazl Tumori, Genoa, Italy Ist Nazl Tumori Genoa ItalyIst Nazl Tumori, Genoa, Italy Forza Operat Italiana Canc Polmone, Genoa, Italy Forza Operat Italiana Canc Polmone Genoa Italy nc Polmone, Genoa, Italy Osped Ivrea, Ivrea, Italy Osped Ivrea Ivrea ItalyOsped Ivrea, Ivrea, Italy
Titolo Testata:
CANCER
fascicolo: 3, volume: 92, anno: 2001,
pagine: 650 - 656
SICI:
0008-543X(20010801)92:3<650:CROCDA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOUTHWEST-ONCOLOGY-GROUP; GELATINASE PRODUCTION; CARCINOMA CELLS; CLINICAL-TRIALS; MITOMYCIN-C; NUDE-MICE; COMBINATION; THERAPY; BETA; CHEMOIMMUNOTHERAPY;
Keywords:
malignant mesothelioma; chemotherapy; interferon; combined modalities; immunotherapy; doxorubicin; cisplatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Parra, HS Ist Clin Humanitas, Dept Med Oncol & Hematol, Via Manzoni 56, I-20089 Rozzano Milano, Italy Ist Clin Humanitas Via Manzoni 56 Rozzano Milano Italy I-20089
Citazione:
H.S. Parra et al., "Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in thetreatment of advanced malignant pleural mesothelioma - A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)", CANCER, 92(3), 2001, pp. 650-656

Abstract

BACKGROUND. The cisplatin-doxorubicin combination has shown moderate activity in malignant pleural mesothelioma (MPM; objective response, 25%), and preclinical studies suggest that interferons (IFNs) may have an antiproliferative effect on mesothelioma cell lines with a marked increase in cisplatincytotoxicity. Therefore, the combined chemoimmunotherapy regimen is an worthwhile approach to evaluate in a Phase II trial. METHODS. From December 1995 to June 1999, 37 previously untreated patientswith MPM were treated with cisplatin 60 mg/m(2) intravenously on Day 1 plus doxorubicin 60 mg/m(2), recycled every 3-4 weeks and IFN-alpha -2b, 3 x 10(6) international. units subcutaneously 3 times a week for a total of 6 courses or until progression. Inclusion criteria were histologic diagnosis ofMPM and measurable disease defined by computed tomography scan or magneticresonance imaging. RESULTS. Thirty-four patients were assessable for toxicity and 35 for efficacy according to World Health Organization criteria. One hundred thirty-five courses were administered with a median of 4 cycles per patients. Seventy-six percent of patient presented at least 1 episode of severe myelosuppresion (Grade 3 and 4). Severe anemia and thrombocytopenia occurred in 30% and 24% of patients, respectively. Sixty percent of patients presented constitutional symptoms. In the 35 patients assessable for response, the overall response rate was 29% (95% confidence interval, 15-47%). The median duration of response was 8.4 months. With a median follow-up of 19.6 months, the median survival was 9.3 months. One- and 2-year survival was 45% and 34%, respectively. CONCLUSIONS. This combined regimen has definite activity in MPM. However, toxicity, particularly myelosuppression and fatigue, is not negligible and may limit its application. Cancer 2001;92:650-6. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 02:33:23